Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ZLAB
ZLAB logo

ZLAB Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
20.780
Open
19.890
VWAP
20.34
Vol
1.25M
Mkt Cap
2.08B
Low
19.890
Amount
25.34M
EV/EBITDA(TTM)
--
Total Shares
110.64M
EV
1.60B
EV/OCF(TTM)
--
P/S(TTM)
4.16
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Show More

Events Timeline

(ET)
2026-04-01
07:40:00
Zai Lab Collaborates with Amgen on Clinical Trial for zocilurtatug
select
2026-02-26 (ET)
2026-02-26
08:00:00
Zai Lab Reports Q4 Revenue of $127.6M
select
2026-01-06 (ET)
2026-01-06
07:40:00
Zai Lab Receives Approval for Augtryo to Treat Adult Solid Tumors
select
2025-12-24 (ET)
2025-12-24
10:10:00
Zai Lab Shares Rise 7.4% to $18.77
select

News

seekingalpha
7.5
15:11 PMseekingalpha
Zai Lab Partners with Amgen for Global Clinical Trial
  • Global Clinical Trial Collaboration: Zai Lab announced a collaboration with Amgen to conduct a global clinical trial studying its antibody-drug conjugate zocilurtatug pelitecan in combination with Amgen's bispecific T-cell engager Imdelltra, marking a strategic move in the small cell lung cancer space.
  • Clinical Trial Phase: Amgen will sponsor a global Phase 1b study to evaluate the drug combination in patients with extensive-stage small cell lung cancer, which accounts for about two-thirds of SCLC cases, indicating the potential market size of this collaboration.
  • Ownership and Supply of Drug: Zai Lab will retain full ownership of zocilurtatug pelitecan and supply the experimental therapy for the Amgen-led study, ensuring control over the development process while potentially enhancing its market competitiveness.
  • Market Outlook for SCLC: Small cell lung cancer accounts for 15% of nearly 2.5 million lung cancer cases diagnosed globally each year, with extensive-stage SCLC having high relapse rates and poor prognosis, highlighting the urgent need for new therapies, and Zai Lab's collaboration aims to address this market gap.
Newsfilter
7.5
11:43 AMNewsfilter
Zai Lab Collaborates with Amgen for Clinical Trial
  • Clinical Collaboration Agreement: Zai Lab has entered into a global clinical trial collaboration with Amgen to evaluate the safety and efficacy of DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan in combination with IMDELLTRA®, marking a strategic move in the treatment of small cell lung cancer.
  • Global Study Launch: Amgen will sponsor a global Phase 1b study while Zai Lab retains full ownership of zocilurtatug pelitecan, which is expected to drive the development of new therapies and enhance the company's competitiveness in the oncology market.
  • Efficacy Potential: Zocilurtatug pelitecan has demonstrated a high response rate at the EORTC-NCI-AACR and ASCO meetings, particularly showing significant intracranial activity in heavily pretreated small cell lung cancer patients, potentially offering new treatment options for this challenging disease.
  • Market Outlook: With poor prognosis for small cell lung cancer patients, and IMDELLTRA® already FDA-approved, the combination of zocilurtatug pelitecan and IMDELLTRA® is poised to further improve efficacy, addressing the urgent market demand for new therapies.
Newsfilter
8.5
03-17Newsfilter
Zai Lab Showcases Innovative ADCs at AACR 2026
  • Drug Presentation: Zai Lab's ADCs ZL-6201 and ZL-1222 will be showcased at the 2026 AACR Annual Meeting, highlighting their potential in treating sarcomas and solid tumors, which is expected to attract investor interest and enhance the company's market profile.
  • Clinical Trial Progress: Zoci's clinical trials for small cell lung cancer demonstrate promising intracranial responses, with plans for three registration-enabling studies by the end of 2026, potentially establishing it as the first global oncology launch for the company and solidifying its leadership in cancer treatment.
  • Innovative Treatment Strategy: ZL-6201, as the first LRRC15-targeting ADC, shows promise for multiple solid tumors, potentially transforming existing treatment standards and improving patient survival rates, thereby enhancing the company's market position.
  • New Direction in Immunotherapy: ZL-1222 aims to overcome PD-1 resistance as a next-generation immunocytokine therapy, enhancing antitumor immunity; if successful, it could open new revenue streams and strengthen the company's competitive edge in the immunotherapy sector.
seekingalpha
9.5
02-26seekingalpha
Zai Lab's Q4 2025 Earnings Call Highlights Global Innovation and Pipeline Progress
  • Significant Revenue Growth: Zai Lab reported total revenue of $127.6 million in Q4 2025, a 17% year-over-year increase, with full-year revenue reaching $460.2 million, up 15%, demonstrating strong performance driven by contributions from XACDURO and NUZYRA.
  • Rapid R&D Progress: Zoci showed an 80% objective response rate in untreated brain metastases patients with a favorable safety profile, with management emphasizing its advancement to global Phase III trials within two years, targeting U.S. approval by 2028, marking a significant breakthrough in oncology.
  • Strategic Transition Year: Management views 2026 as a transition year focused on execution and upcoming launches, and while full-year financial guidance was not provided, the expectation is to leverage a robust pipeline and strong cash position to drive long-term growth, reflecting confidence in future market opportunities.
  • Effective Cost Control: R&D expenses declined by 6% for the full year, while SG&A expenses decreased by 12% in Q4, leading to a 19% improvement in operating loss to $229.4 million, showcasing the company's success in enhancing operational leverage and financial flexibility, strengthening its position in a competitive market.
seekingalpha
9.5
02-25seekingalpha
Zai Lab Scheduled to Announce Q4 Earnings on February 26
  • Earnings Announcement Date: Zai Lab (ZLAB) is set to announce its Q4 2023 earnings on February 26 before market open, drawing increased attention from investors amid a competitive biopharmaceutical landscape.
  • Earnings Expectations: The consensus EPS estimate stands at -$0.42, reflecting a 47.5% year-over-year improvement, indicating some progress in the company's efforts to enhance profitability despite remaining in the red.
  • Revenue Expectations: The consensus revenue estimate is $122.67 million, representing a 12.4% year-over-year increase, highlighting Zai Lab's potential for sales growth as market demand recovers.
  • Estimate Revisions: Over the past three months, EPS estimates have seen one upward revision and three downward adjustments, while revenue estimates have faced five downward revisions with no upward changes, suggesting analysts' cautious outlook on the company's future performance.
moomoo
4.0
02-20moomoo
ZAI LAB LTD: CITIGROUP LOWERS TARGET PRICE FROM $58 TO $53
  • Company Announcement: Zailab Ltd. has announced a reduction in its target price.
  • New Target Price: The target price has been cut from $58 to $53.
Wall Street analysts forecast ZLAB stock price to rise
5 Analyst Rating
Wall Street analysts forecast ZLAB stock price to rise
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
25.70
Averages
47.93
High
74.00
Current: 0.000
sliders
Low
25.70
Averages
47.93
High
74.00
JPMorgan
Anupam Rama
Overweight
downgrade
$39 -> $32
AI Analysis
2026-03-18
Reason
JPMorgan
Anupam Rama
Price Target
$39 -> $32
AI Analysis
2026-03-18
downgrade
Overweight
Reason
JPMorgan analyst Anupam Rama lowered the firm's price target on Zai Lab to $32 from $39 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology space.
Cantor Fitzgerald
Overweight
downgrade
$55 -> $37
2026-02-27
Reason
Cantor Fitzgerald
Price Target
$55 -> $37
2026-02-27
downgrade
Overweight
Reason
Cantor Fitzgerald lowered the firm's price target on Zai Lab to $37 from $55 and keeps an Overweight rating on the shares. Zai Lab reported Q4 and full-year revenues of $127.6M and $460.2M, respectively, in line with consensus, though Vyvgart sales were slightly weaker than expected, the analyst tells investors in a research note. Management indicated that 2026 top-line growth is likely to be modest, with volume gains offset by pricing pressures and competition in China, the firm says.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ZLAB
Unlock Now

Valuation Metrics

The current forward P/E ratio for Zai Lab Ltd (ZLAB.O) is 0.00, compared to its 5-year average forward P/E of -17.96. For a more detailed relative valuation and DCF analysis to assess Zai Lab Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-17.96
Current PE
0.00
Overvalued PE
3.10
Undervalued PE
-39.02

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-13.84
Current EV/EBITDA
-7.27
Overvalued EV/EBITDA
0.18
Undervalued EV/EBITDA
-27.85

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
15.67
Current PS
3.28
Overvalued PS
34.84
Undervalued PS
-3.51

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what stock should I trade today
Intellectia · 19 candidates
Market Cap: >= 1000.00MPrice: $5.00 - $100.00Price Change Pct: >= $3.00Beta: HighRiskList Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
PSNY logo
PSNY
Polestar Automotive Holding UK PLC
1.21B
FORM logo
FORM
FormFactor Inc
5.43B
AXTI logo
AXTI
AXT Inc
1.11B
OCUL logo
OCUL
Ocular Therapeutix Inc
1.80B
BLBD logo
BLBD
Blue Bird Corp
1.58B
KLIC logo
KLIC
Kulicke and Soffa Industries Inc
2.89B

Whales Holding ZLAB

F
Frazier Life Sciences Management, LP
Holding
ZLAB
+5.29%
3M Return
G
Great Wall Fund Management Co., Ltd
Holding
ZLAB
-1.52%
3M Return
R
RTW Investments, LP
Holding
ZLAB
-3.28%
3M Return
R
Rock Springs Capital Management LP
Holding
ZLAB
-5.31%
3M Return
Q
Qiming Weichuang Venture Capital Management (Shanghai) Company Limited
Holding
ZLAB
-8.54%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Zai Lab Ltd (ZLAB) stock price today?

The current price of ZLAB is 20.34 USD — it has increased 8.13

What is Zai Lab Ltd (ZLAB)'s business?

Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.

What is the price predicton of ZLAB Stock?

Wall Street analysts forecast ZLAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZLAB is47.93 USD with a low forecast of 25.70 USD and a high forecast of 74.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Zai Lab Ltd (ZLAB)'s revenue for the last quarter?

Zai Lab Ltd revenue for the last quarter amounts to 127.60M USD, increased 16.99

What is Zai Lab Ltd (ZLAB)'s earnings per share (EPS) for the last quarter?

Zai Lab Ltd. EPS for the last quarter amounts to -0.05 USD, decreased -37.50

How many employees does Zai Lab Ltd (ZLAB). have?

Zai Lab Ltd (ZLAB) has 1784 emplpoyees as of April 01 2026.

What is Zai Lab Ltd (ZLAB) market cap?

Today ZLAB has the market capitalization of 2.08B USD.